1 / 28

Heart Care Centers of Illinois

Heart Care Centers of Illinois. Design. Single arm, open label, 13 U.S. centers Patients with ST-segment elevation myocardial infarction (STEMI) Less than 12 hours duration No prior thrombolytic therapy Primary PCI required

ellis
Download Presentation

Heart Care Centers of Illinois

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Heart Care Centers of Illinois

  2. Design • Single arm, open label, 13 U.S. centers • Patients with ST-segment elevation myocardial infarction (STEMI) • Less than 12 hours duration • No prior thrombolytic therapy • Primary PCI required • Patient population matched to CADILLAC by inclusion and exclusion criteria • Comparable efficacy endpoints

  3. Design (cont.) • Treatment: Bivalirudin 0.75mg/kg bolus, 1.75mg/kg/hr infusion for duration of procedure • Optional post-procedure infusion: 0.25mg/kg/hr • Abciximab if TIMI flow <3 at end of procedure • Primary endpoints of safety and efficacy evaluated at 7 days/hospital discharge, 30 days and 6 months

  4. Inclusion Criteria • Symptoms of STEMI for at least 30 min within previous 12 hours AND • ST-segment elevation in at least 2 contiguous leads or new LBBB or existing LBBB with positive troponin • Residual high grade stenosis and associated abnormalities in regional wall motion. • Planned primary PCI in native coronary vessel

  5. Exclusion Criteria • Prior LMWH, Thrombolytics, GP IIb/IIIa inhibitors • Cardiogenic shock (SBP <80 for >30 min or a need for intravenous pressors) • Stroke or neurosurgery within 3 months • Severe hypertension not adequately controlled by antihypertensive therapy at the time of study entry (BP >180/110 mm Hg) • Life expectancy <1 year • Heparin only therapy allowed prior to PCI • 30 minute washout, or • ACT <250

  6. Primary Endpoints • EfficacyEvaluated at 7 days/hospital discharge, at 30 days, and 6 months composite and individual components of: • Death (cardiac and unknown cause) • Reinfarction • Repeat intervention/revascularization of target lesion as a result of ischemia • Disabling stroke • Rate of subacute thrombosis at 7 days/hospital discharge and at 30 days

  7. Primary Endpoints • SafetyEvaluated at 7 days/hospital discharge: • Clinically significant bleeding defined as: • Intracranial, retroperitoneal, or ocular bleeding • Access site hemorrhage requiring surgical intervention or a >5cm diameter hematoma • Reduction in Hgb concentration of >3g/dL with overt bleeding • Any blood transfusion • Any reoperation for bleeding • Thrombocytopenia (<100,000 cells/L with a fall of >50% from baseline)

  8. BIAMI Sites

  9. Enrollment and Follow-up Patients Enrolled 201 ITT 201 PCI successful 194 Cath Only 4 PCI unsuccessful 3 Safety 201 7-day 201 30-day 197 4 patients lost to f/u 6-month 190 11 patients lost to f/u Ed. 4/19

  10. CADILLAC • Comparison with CADILLAC entry criteria and efficacy prespecified in protocol • CADILLAC, 2082 AMI patients, 2x2 factorial design (PTCA or stent with and without abciximab) • Abciximab/stent group (n=524) used as comparison • Highest % TIMI 3 flow rate end of procedure • Lowest composite endpoint at 30 days and 6 months G. Stone M.D., C. Grines M.D., D. Cox M.D. N Engl J Med, Vol. 346, No. 13 March 28, 2002

  11. Patient Characteristics CADILLAC Comparison

  12. Target Vessel/Lesion Characteristics Ed 5/9

  13. PCI Therapy Stentsn • Drug Eluting Stents 123 • Cypher 69 • Taxus 64 • Bare Metal Stents 54 • Drug Eluting and Bare Metal 10 • Thrombectomy 16

  14. Anticoagulation • All patients received bivalirudin during their PCI • 60% of patients received UFH before their intervention • 40% of patients received NO UFH, only bivalirudin • NO significant bleeding occurred in the patient population that received BOTH UFH and bivalirudin • Mean ACT 189 seconds in patients who received UFH.

  15. Concomitant Meds

  16. Concomitant Meds n/N 20/197 12/20 % 10.1 60.0 • Abciximab bolus and infusion • Administration for less than TIMI-3 flow post procedure • TIMI-3 flow achieved post-Abcixmab

  17. Of the 194 patients with a successful PCI, 86 required post-procedure anticoagulation: Angiomax® 64 patients Heparin 14 patients Both 8 patients

  18. Post Procedure Heparin (non CABG) • Reasons for heparin continuation • IABP • Transition to Warfarin • DVT / PE prophylaxis • Other

  19. Post Procedure Angiomax® (non CABG) * Only 25 patients had greater than 30 minutes Angiomax

  20. Pre/Post-Procedure TIMI Flow * Visible Thrombus present prior to procedure in 61.2% of patients. Ed 4/21

  21. Primary Endpoint * Both strokes post CABG** SAT not collected to 6 months Ed. 5/9

  22. Efficacy 30 days: Patient Details 03/23

  23. Efficacy 30 days: Patient Details contd. 03/23

  24. Deaths at 30 days : Patient Details

  25. Bleeding Endpoint • All bleeds had post procedural anticoagulation Ed 5/9

  26. Clinically Significant Bleeding : Details All bleeds had post procedural anticoagulation/antiplatelet Ed 04/21

  27. 30-Day Clinical Outcomes Comparison to CADILLAC * Two Strokes Post CABG Ed. 5/9

  28. 6-Month Clinical Outcomes Comparison to CADILLAC * Two Strokes Post CABG Ed. 4/18

More Related